SyntheX uses synthetic biology to create the next generation of drug discovery platforms. Using genetically engineered circuits, we rely on intracellular drug selection as opposed to in-vitro screening. This allows us to discover unbiased compounds with novel modes of action that can engage targets in either competitive or allosteric ways. We have developed ToRPPIDO to discover disruptors of protein-protein interactions (PPIs), and ToRNeDO to discover functional molecular glues for degraders of a neosubstrate of interest with a desired E3 ligase.
In the same cells, we incorporate our proprietary DNA-encoded libraries of peptides and macrocycles to enable the production and selection of molecules in an efficient and high throughput manner.
Our lead programs focus on oncology.
Location: United States, California, San Francisco
Member count: 11-50
Founded date: 2016
Investors 2
| Date | Name | Website |
| - | MBC BioLab... | mbcbiolabs... |
| - | OMX Ventur... | omx.vc |
Mentions in press and media 2
| Date | Title | Description | Category | Author | Source |
| 25.04.2019 | The ventur... | SOSV, a multi-stage venture fi... | sosv | Connie Loi... | techcrunch... |
| 12.07.2016 | Watch the ... | TechCrunch is pleased to bring... | DemoDayTV,... | Samantha O... | techcrunch... |